These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Ongoing||2013-001640-56||Crossover clinical trial, randomized, double blind, placebo controlled trial. Modulation of cellular mediators and repair endothelial damage in patients with chronic renal disease through inhibition o...||not-yet-due|
|Ongoing||2014-002850-38||EFFICACY AND SAFETY OF EARLY POSTOPERATIVE CHEMOTHERAPY INTRAPERITONEAL (EPIC) WITH PACLITAXEL IN THE RADICAL SURGERY TREATMENT OF OVARIAN PERITONEAL CARCINOMATOSIS||not-yet-due|
|Not reported Terminated||2015-004530-94||Pilot study (Phase II) of Pomalidomide, oral Desamethasone and very low-dose Cyclophosphamide in patients with refractory Multiple Myeloma who have received Lenalidomide and Bortezomib.||2019-05-07||due-trials|
|Ongoing||2018-003300-39||Clinical trial of efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis in lung transplant recipients.||not-yet-due|
|Ongoing||2020-001531-27||Clinical trial of Sarilumab in adults hospitalized with COVID-19 presenting cytokine release syndrome||not-yet-due|
|Ongoing||2020-001541-39||Pilot study of single-dose bevacizumab as a treatment for acute respiratory distress syndrome in patients with COVID-19||not-yet-due|
|Ongoing||2020-001659-42||Pilot study of antithrombin as prophylaxis of acute respiratory distress syndrome in patients with COVID-19||not-yet-due|
|Ongoing||2020-001717-20||Prevention and treatment with Calcifediol of Coronavirus COVID-19-induced acute respiratory syndrome (SARS)||not-yet-due|